메뉴 건너뛰기




Volumn 11, Issue 4, 1997, Pages 469-475

Three-drug combination of MKC-442, lamivudine and zidovodine in vitro: Potential approach towards effective chemotherapy against HIV-1

Author keywords

Combination chemotherapy; HIV 1; Reverse transcriptase inhibitor

Indexed keywords

ANTIVIRUS AGENT; EMIVIRINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME; ZIDOVUDINE;

EID: 0031047323     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199704000-00010     Document Type: Article
Times cited : (15)

References (28)
  • 1
    • 0029984359 scopus 로고    scopus 로고
    • Combination therapy for HIV-1 infection. Overview: Preclinical and clinical analysis of antiretroviral combinations
    • Johnson VA: Combination therapy for HIV-1 infection. Overview: preclinical and clinical analysis of antiretroviral combinations. Antiviral Res 1996, 29:35-39.
    • (1996) Antiviral Res , vol.29 , pp. 35-39
    • Johnson, V.A.1
  • 2
    • 0028331215 scopus 로고
    • Combination therapy for infection due to human immunodeficiency virus type 1
    • Caliendo AM, Hirsch MS: Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994, 18:516-524.
    • (1994) Clin Infect Dis , vol.18 , pp. 516-524
    • Caliendo, A.M.1    Hirsch, M.S.2
  • 3
    • 0029877789 scopus 로고    scopus 로고
    • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development
    • De Clercq E: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med Res Rev 1996, 16:125-157.
    • (1996) Med Res Rev , vol.16 , pp. 125-157
    • De Clercq, E.1
  • 4
    • 0029079399 scopus 로고
    • Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1- Specific inhibitors (i.e., TSAO derivatives)
    • Balzarini J, Perez-Perez MJ, Velazquez S, et al.: Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1- specific inhibitors (i.e., TSAO derivatives). Proc Natl Acad Sci USA 1995, 92:5470-5474.
    • (1995) Proc Natl Acad Sci USA , vol.92 , pp. 5470-5474
    • Balzarini, J.1    Perez-Perez, M.J.2    Velazquez, S.3
  • 5
    • 0028837503 scopus 로고
    • Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease
    • Fischl MA, Stanley K, Collier AC, et al.: Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995, 122:24-32.
    • (1995) Ann Intern Med , vol.122 , pp. 24-32
    • Fischl, M.A.1    Stanley, K.2    Collier, A.C.3
  • 6
    • 10144244674 scopus 로고    scopus 로고
    • A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
    • Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
    • (1996) N Engl J Med , vol.335 , pp. 1081-1090
    • Hammer, S.M.1    Katzenstein, D.A.2    Hughes, M.D.3
  • 7
    • 9444290697 scopus 로고    scopus 로고
    • Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy
    • Schooley RT, Ramirez-Ronda C, Lange JMA, et al.: Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996, 173:1354-1366.
    • (1996) J Infect Dis , vol.173 , pp. 1354-1366
    • Schooley, R.T.1    Ramirez-Ronda, C.2    Lange, J.M.A.3
  • 8
    • 8044227182 scopus 로고    scopus 로고
    • Effect of nucleoside analogue RT inhibitors on plasma HIV RNA and CD4 count as an indicator of clinical effect
    • Vancouver, July [abstract MoB290]
    • Phillips AN, Fron J, Bartlett J, Hill AM, The North American Lamivudine HIV Working Group: Effect of nucleoside analogue RT inhibitors on plasma HIV RNA and CD4 count as an indicator of clinical effect. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB290].
    • (1996) XI International Conference on AIDS
    • Phillips, A.N.1    Fron, J.2    Bartlett, J.3    Hill, A.M.4
  • 9
    • 0029563673 scopus 로고
    • Treatment with lamivudine, zidovudine, or both in positive patients with 200 to 500 CD4+ clls per cubic millimiter
    • Eron JJ, Benot SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in positive patients with 200 to 500 CD4+ clls per cubic millimiter. N Engl J Med 1995, 333:1662-1669.
    • (1995) N Engl J Med , vol.333 , pp. 1662-1669
    • Eron, J.J.1    Benot, S.L.2    Jemsek, J.3
  • 10
    • 8044231931 scopus 로고
    • The Interim safety results and pharmacokinetics of a combination of R89439 and zidovudine therapy in HIV-infection
    • Yokohama. August [abstract PB0252]
    • Colebunders R, Vandenbruaene M, Delescluse J. et al.: The Interim safety results and pharmacokinetics of a combination of R89439 and zidovudine therapy in HIV-infection. X International Conference on AIDS. Yokohama. August 1994 [abstract PB0252].
    • (1994) X International Conference on AIDS
    • Colebunders, R.1    Vandenbruaene, M.2    Delescluse, J.3
  • 11
    • 9244247314 scopus 로고
    • Randomized double-blind trial of loviride (R89439) (L), zidovudine (Z) and the combination in HIV-1 infected patients
    • Washington, DC, January-February [abstract LB6A]
    • Youle M, Davies S, Andries K, et al.: Randomized double-blind trial of loviride (R89439) (L), zidovudine (Z) and the combination in HIV-1 infected patients. Second National Conference on Human Retroviruses and Related Infection. Washington, DC, January-February 1995 [abstract LB6A].
    • (1995) Second National Conference on Human Retroviruses and Related Infection
    • Youle, M.1    Davies, S.2    Andries, K.3
  • 12
    • 9244220064 scopus 로고    scopus 로고
    • Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients
    • Staszewski S, Miller V, Rehmet S, et al.: Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996, 10:F1-F7.
    • (1996) AIDS , vol.10
    • Staszewski, S.1    Miller, V.2    Rehmet, S.3
  • 13
    • 0030317268 scopus 로고    scopus 로고
    • Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1-infection
    • D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1-infection. Ann Intern Med 1996, 124:1019-1030.
    • (1996) Ann Intern Med , vol.124 , pp. 1019-1030
    • D'Aquila, R.T.1    Hughes, M.D.2    Johnson, V.A.3
  • 14
    • 0027285372 scopus 로고
    • Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
    • Tisdale M, Kemp D, Parry N, Larber B: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 5653-5656
    • Tisdale, M.1    Kemp, D.2    Parry, N.3    Larber, B.4
  • 15
    • 0029028067 scopus 로고
    • Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
    • Larder BA, Kemp DK, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
    • (1995) Science , vol.269 , pp. 696-699
    • Larder, B.A.1    Kemp, D.K.2    Harrigan, P.R.3
  • 16
    • 0025950055 scopus 로고
    • Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
    • St Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
    • (1991) Science , vol.253 , pp. 1557-1559
    • St Clair, M.H.1    Martin, J.L.2    Tudor-Williams, G.3
  • 17
    • 0026454435 scopus 로고
    • 3′-Azido-3′-deoxythimidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
    • Larder BA: 3′-Azido-3′-deoxythimidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
    • (1992) Antimicrob Agents Chemother , vol.36 , pp. 2664-2669
    • Larder, B.A.1
  • 18
    • 0028329454 scopus 로고
    • Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro
    • Baba M, Shigeta S, Yausa S, et al.: Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 1994, 38:688-692.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 688-692
    • Baba, M.1    Shigeta, S.2    Yausa, S.3
  • 19
    • 0027436898 scopus 로고
    • Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleotide inhibitor, MKC-442
    • Yuasa S, Sadakata Y, Takashima H, et al.: Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleotide inhibitor, MKC-442. Mol Pharmacol 1993, 44:895-900.
    • (1993) Mol Pharmacol , vol.44 , pp. 895-900
    • Yuasa, S.1    Sadakata, Y.2    Takashima, H.3
  • 20
    • 0029944278 scopus 로고    scopus 로고
    • Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells
    • Okamoto M, Makino M, Yamada K, Nakade K, Yuasa S, Baba M: Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells. Antiviral Res 1996, 31:69-77.
    • (1996) Antiviral Res , vol.31 , pp. 69-77
    • Okamoto, M.1    Makino, M.2    Yamada, K.3    Nakade, K.4    Yuasa, S.5    Baba, M.6
  • 21
    • 0029922342 scopus 로고    scopus 로고
    • Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-) 2′,3′-dideoxy-3′-thiacytidine
    • Balzarini J, Pelemans H, Perez-Perez M-J, et al.: Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-) 2′,3′-dideoxy-3′-thiacytidine. Mol Pharmacol 1996, 49:882-890.
    • (1996) Mol Pharmacol , vol.49 , pp. 882-890
    • Balzarini, J.1    Pelemans, H.2    Perez-Perez, M.-J.3
  • 22
    • 0020261516 scopus 로고
    • Type C virus producing cell lines derived from adult T cell leukemia
    • Miyoshi I, Taguchi H, Kubonishi I, et al.: Type C virus producing cell lines derived from adult T cell leukemia. Gann Monogr 1982, 28:219-228.
    • (1982) Gann Monogr , vol.28 , pp. 219-228
    • Miyoshi, I.1    Taguchi, H.2    Kubonishi, I.3
  • 23
    • 0029096567 scopus 로고
    • Synthesis and antiviral activity of 6-benzil analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti HIV-1 drugs
    • Tanaka H, Takashima H, Ubasawa M, et al.: Synthesis and antiviral activity of 6-benzil analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti HIV-1 drugs. J Med Chem 1995, 38:2860-2865.
    • (1995) J Med Chem , vol.38 , pp. 2860-2865
    • Tanaka, H.1    Takashima, H.2    Ubasawa, M.3
  • 24
    • 0023687234 scopus 로고
    • Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
    • Pauwels R, Balzarini J, Baba M, et al.: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988, 20: 309-321.
    • (1988) J Virol Methods , vol.20 , pp. 309-321
    • Pauwels, R.1    Balzarini, J.2    Baba, M.3
  • 25
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationship: The combined effects of multiple drugs or enzyme inhibitors
    • Chou TC, Talalaly P: Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
    • (1984) Adv Enzyme Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalaly, P.2
  • 26
    • 0028003745 scopus 로고
    • Multiple drug effect analysis with confidence interval
    • Belen'kii MS, Schinazi RS: Multiple drug effect analysis with confidence interval. Antiviral Res 1994, 25:1-11.
    • (1994) Antiviral Res , vol.25 , pp. 1-11
    • Belen'kii, M.S.1    Schinazi, R.S.2
  • 27
    • 0028958591 scopus 로고
    • Isolation and characterization of human immunodeficiency virus type 1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442
    • Seki M, Sadakata Y, Yuasa S, Baba M: Isolation and characterization of human immunodeficiency virus type 1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442. Antiviral Chem Chemother 1995, 6:73-79.
    • (1995) Antiviral Chem Chemother , vol.6 , pp. 73-79
    • Seki, M.1    Sadakata, Y.2    Yuasa, S.3    Baba, M.4
  • 28
    • 0029024089 scopus 로고
    • Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus population in person treated with lamivudine (3TC)
    • Schuurman R, Nijhuis M, van-Leeuven R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus population in person treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
    • (1995) J Infect Dis , vol.171 , pp. 1411-1419
    • Schuurman, R.1    Nijhuis, M.2    Van-Leeuven, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.